Acute liver and renal failure during treatment with buprenorphine at therapeutic dose

Digestive and Liver Disease

Volumn 41, Issue 7, 2009, Pages

  Zuin, M ^a   Giorgini, A ^a   Selmi, C ^a   Battezzati, P M ^a   Cocchi, C A ^a   Crosignani, A ^a   Benetti, A ^a   Invernizzi, P ^a   Podda, M ^a  

^a San Paolo School of Medicine   (Italy)

Author keywords

Drug induced hepatotoxicity; Nephrotoxicity; Pharmacogenetics

Indexed keywords

BUPRENORPHINE;

ADULT; ANURIA; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; ECHOGRAPHY; FATTY LIVER; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HEROIN DEPENDENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LABORATORY TEST; LATENT VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ADULT; BUPRENORPHINE; HEROIN DEPENDENCE; HUMANS; KIDNEY FAILURE, ACUTE; LIVER FAILURE, ACUTE; MALE; NARCOTIC ANTAGONISTS;

EID: 67349212110     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.12.014     Document Type: Article

References (18)

1. Law F.D., and Nutt D.J. Maintenance buprenorphine for opioid users. Lancet 361 (2003) 634-635
2. Walsh S.L., and Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 70 (2003) S13-S27
3. Berson A., Fau D., Fornacciari R., Degove-Goddard P., Sutton A., Descatoire V., et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 34 (2001) 261-269
4. Han Y., Chawarski M.C., Pantalon M.V., and Schottenfeld R.S. Liver enzyme abnormalities during buprenorphine versus methadone maintenance. Drug Alcohol Depend 66 (2002) S74
5. Herve S., Riachi G., Noblet C., Guillement N., Tanasescu S., Goria O., et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 16 (2004) 1033-1037
6. Benedetti M.S. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14 (2000) 301-319
7. Ramsay R.E. Clinical efficacy and safety of gabapentin. Neurology 44 (1994) S23-S30 [discussion S31-22]
8. Nims R.W., Prough R.A., Jones C.R., Stockus D.L., Dragnev K.H., Thomas P.E., et al. In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Drug Metab Dispos 25 (1997) 750-756
9. Petry N.M., Bickel W.K., Piasecki D., Marsch L.A., and Badger G.J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 9 (2000) 265-269
10. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 22 (2002) 145-155
11. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., and Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 55 (1994) 569-580
12. Kobayashi K., Yamamoto T., Chiba K., Tani M., Shimada N., Ishizaki T., et al. Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26 (1998) 818-821
13. Tegeder I., Lotsch J., and Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 37 (1999) 17-40
14. Guengerich F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
15. Xie H.G., Kim R.B., Wood A.J., and Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41 (2001) 815-850
16. Dai D., Tang J., Rose R., Hodgson E., Bienstock R.J., Mohrenweiser H.W., et al. Identification of variants of CYP 3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299 (2001) 825-831
17. Krahenbuhl S. Mitochondria: important target for drug toxicity?. J Hepatol 34 (2001) 334-336
18. Boger R.H. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 20 Suppl. 1 (2006) s17-s23